[HTML] frontiersin.org

[HTML][HTML] Beyond bevacizumab: an outlook to new anti-angiogenics for the treatment of ovarian cancer

S Mahner, L Woelber, V Mueller, I Witzel… - Frontiers in …, 2015 - frontiersin.org
In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody
bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer …
被引用次数：23 相关文章

Beyond bevacizumab: an outlook to new anti-angiogenics for the treatment of ovarian cancer

S Mahner, L Woelber, V Mueller… - Frontiers in …, 2015 - epub.ub.uni-muenchen.de
In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody
bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer …

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer.

S Mahner, L Woelber, V Mueller, I Witzel… - Frontiers in …, 2015 - europepmc.org
In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody
bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer …
[HTML] nih.gov

[HTML][HTML] Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer

S Mahner, L Woelber, V Mueller, I Witzel… - Frontiers in …, 2015 - ncbi.nlm.nih.gov
In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody
bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer …
[PDF] core.ac.uk

[PDF][PDF] Beyond bevacizumab: an outlook to new anti-angiogenics for the treatment of ovarian cancer

S Mahner, L Woelber, V Mueller, I Witzel… - Frontiers in …, 2015 - core.ac.uk
In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody
bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer …

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer

S Mahner, L Woelber, V Mueller, I Witzel… - Frontiers in …, 2015 - pubmed.ncbi.nlm.nih.gov
In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody
bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer …
[PDF] psu.edu

[PDF][PDF] Beyond bevacizumab: an outlook to new anti-angiogenics for the treatment of ovarian cancer

S Mahner, L Woelber, V Mueller, I Witzel, K Prieske… - Frontiers in …, 2015 - Citeseer
In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody
bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer …
[PDF] researchgate.net

[PDF][PDF] Beyond bevacizumab: an outlook to new anti-angiogenics for the treatment of ovarian cancer

S Mahner, L Woelber, V Mueller, I Witzel… - Frontiers in …, 2015 - researchgate.net
In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody
bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer …
[PDF] core.ac.uk

[PDF][PDF] Beyond bevacizumab: an outlook to new anti-angiogenics for the treatment of ovarian cancer

S Mahner, L Woelber, V Mueller, I Witzel… - Frontiers in …, 2015 - core.ac.uk
In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody
bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer …

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer

S Mahner, L Woelber, V Mueller, I Witzel… - Frontiers in …, 2015 - pubmed.ncbi.nlm.nih.gov
In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody
bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer …